Treatment | History of OAPS (N:9) | History of TAPS (N:25) | History of OAPS+TAPS (N:24) | No TAPS/OAPS (N:19) | ||||
# of patients | Pregnancy morbidity | # of patients | Pregnancy morbidity | # of patients | Pregnancy morbidity | # of patients | Pregnancy morbidity | |
LDA | 2 | FD:1 EPL:1 | 1 | – | – | – | 4 | PTLD:1 FD:1 EPL:1 |
Prophylactic dose LMWH | – | – | – | – | 1 | – | 1 | – |
Therapeutic dose LMWH | – | – | 2 | FD:1 | 1 | – | 1 | – |
LDA+prophylactic dose LMWH | 4 | PTLD+SGA:1 EPL:1 | 2 | – | 3 | TLD+PEC:1 EPL:1 | 5 | TLD+SGA:1 |
LDA+therapeutic dose LWMH | 3 | – | 16 | PTLD:1 PTLD+SGA:1 PTLD+PEC:2 EPL:5 FD:2* | 16 | TLD+SGA+PEC:1 PTLD:2 PTLD+PEC:1 EPL:4 FD:1 | 4 | PTLD:1 PTLD+PEC:2 FD:1* |
LDA+prophylactic dose UFH | – | – | – | – | – | – | 1 | EPL:1 |
No treatment | – | – | 4 | EPL:3 | 3 | FD:1 EPL:2 | 3 | FD:1 EPL:1 |
In 22/67 pregnancies, LDA and/or LMWH started preconceptionally, in 45/67 pregnancies LDA and/or LMWH started after the conception (mean and median gestational weeks of treatment initiation are 4.6 weeks and 5 weeks, respectively).
*Fetal death associated with anomalies (triple X syndrome and cystic fibrosis, respectively).
APS, antiphospholipid syndrome; EPL, early pregnancy loss; FD, fetal death; LDA, low-dose aspirin; LMWH, low-molecular-weight heparin; OAPS, obstetric APS; PEC, pre-eclampsia; PTLD, preterm live delivery; SGA, small-for-gestational age; TAPS, thrombotic APS; TLD, term live delivery; UFH, unfractionated heparin.